A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART).
Kota Kawabata, Fumiharu Ohka, Ryuta Saito et al.
✦ AI-curated · Sources linked
In 30 seconds
The JCOG2314 trial is a multicenter, randomized phase II/III study evaluating tirabrutinib as a salvage treatment for refractory primary central nervous system lymphoma (PCNSL) compared to whole-brain radiotherapy (WBRT). The study aims to determine tirabrutinib's non-inferiority in overall survival while potentially reducing functional deterioration and cognitive impairment in this patient population.
Key findings
- Tirabrutinib is being compared to WBRT for overall survival in patients with refractory PCNSL.
- The trial will enroll 94 patients across 49 institutions over 4 years.
- Tirabrutinib may reduce concerns of early functional deterioration and late neurocognitive toxicity associated with WBRT.
Why it matters
This study addresses a critical need for effective salvage treatments in patients with refractory PCNSL, who typically face poor prognoses and significant treatment-related toxicities. Understanding the efficacy and safety of tirabrutinib could inform future treatment strategies.